Saturday 17 October 2026
Export BTCY’s income statement to Excel — free account
Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
0.05
0.00
0.00%
Follow BTCY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.94 | 0.54 | 0.41 | 0.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 21.03 | |
P/Operating CF |
34.14 | (11.18) | (313.54) | 5.46 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.62 | 2.24 | 2.07 | 1.77 | |
EV/EBITDA |
113.61 | 38.67 | 13.54 | 12.19 | |
EV/Operating CF |
(88.56) | (31.46) | (45.99) | 179.35 | |
EV/FCF |
(83.02) | (30.63) | (44.16) | 219.90 | |
Quick Ratio |
0.10 | 0.08 | 0.08 | 0.08 | |
Current Ratio |
0.23 | 0.21 | 0.16 | 0.15 | |
Net Debt/EBITDA |
69.21 | 27.06 | 47.60 | 54.32 | |
Debt/Assets |
406.16% | 466.84% | 413.65% | 442.89% | |
Debt/Equity |
(0.77) | (0.78) | (0.77) | (0.75) | |
Asset Turnover |
2.60 | 2.65 | 2.65 | 2.72 | |
Operating CF/Net income |
(0.54) | 0.64 | 0.05 | (0.47) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.32 | 0.54 | 0.83 | 0.19 | |
Research and Development Expense of Revenue |
15.51% | 15.64% | 19.80% | 15.74% | |
Selling, General and Administrative Expense of Revenue |
59.32% | 54.84% | 43.82% | 63.11% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.15% | 1.20% | (0.72%) | 7.95% | |
Graham Net Nets |
(2.41) | (4.22) | (5.38) | (12.93) | |
Graham Number |
2.19 | 2.11 | 1.85 | 2.27 | |
Earnings Yield |
(32.08%) | (53.33%) | (50.00%) | (116.67%) | |
Free Cash Flow Yield |
(3.36%) | (13.64%) | (11.43%) | 4.76% | |
Revenue per Share |
0.15 | 0.14 | 0.16 | 0.19 | |
Operating CF per Share |
0.02 | (0.03) | 0.00 | 0.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.03) | 0.00 | 0.02 | |
Cash per Share |
0.01 | 0.01 | 0.01 | 0.02 | |
Shareholders Equity per Share |
(1.25) | (1.24) | (1.27) | (1.53) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.25) | (1.24) | (1.27) | (1.53) | |
Free Cash Flow |
0.42 | (0.74) | (0.02) | 0.51 | |
Working Capital |
(18.08) | (18.82) | (31.28) | (31.75) | |
Net Current Asset Value |
(34.20) | (34.94) | (35.27) | (35.83) | |
EV/EBIT |
0.00 | 244.99 | 19.55 | 18.49 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 58.66 | 3.87 | 1.77 | |
| Other line items | |||||
Average Receivables |
1.80 | 1.41 | 2.30 | 2.13 | |
Average Payables |
8.48 | 8.47 | 8.32 | 8.58 | |
Average Inventory |
2.04 | 1.77 | 1.45 | 1.60 | |
Average Assets |
5.81 | 5.84 | 6.04 | 6.03 | |
Average Common Equity |
(32.29) | (33.09) | (33.35) | (35.32) |
Columns are period end dates · fundamentals updated 28 Sep 2026